BAY88-8223, Dose Finding Study in Patients With HRPC
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the investigational
radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone
metastases that no longer respond to hormonal treatment.